WHO announced that a fourth WHO-prequalified human papillomavirus vaccine product, Cecolin has been confirmed for use in a single-dose schedule. The decision is made based on new data on the product that fulfilled the criteria set out in the WHO 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.











